アブストラクト
| Title | IgG4関連後腹膜線維症 |
|---|---|
| Subtitle | 特集 IgG4関連疾患大全 - 自己免疫性膵炎とIgG4関連硬化性胆管炎を中心に - IV. その他のIgG4関連疾患の病態, 診断と治療 |
| Authors | 水島伊知郎1), 川野充弘1) |
| Authors (kana) | |
| Organization | 1)金沢大学附属病院リウマチ・膠原病内科 |
| Journal | 胆と膵 |
| Volume | 43 |
| Number | 臨時増刊特大 |
| Page | 1309-1316 |
| Year/Month | 2022 / 10 |
| Article | 報告 |
| Publisher | 医学図書出版 |
| Abstract | 「要約」 : IgG4関連疾患の疾患概念が提唱される以前より, 後腹膜線維症という疾患概念が存在しており, これまでの検討により特発性後腹膜線維症のおよそ半数がIgG4関連後腹膜線維症であるといわれている. 本疾患はIgG4関連疾患に共通する臨床的特徴を呈しつつも, 血清IgG4値低値の傾向, 組織検体採取の困難さ, 合併する水腎症など, 臓器固有の特徴も認められる. 我が国においては, 専門家らによる本疾患診断の現状を考慮して作成された臓器特異的診断基準が存在し, 実臨床における診断精度の検証と改訂が待たれる. ステロイド治療への反応は良好であるが再発も多く, 他の薬物治療や尿路閉塞に対するインターベンションなど, よりよい診療指針の確立のために今後もさらなる検討が必要である. |
| Practice | 臨床医学：内科系 |
| Keywords | IgG4関連疾患, 後腹膜線維症, 水腎症 |
- 全文ダウンロード： 従量制、基本料金制の方共に1,023円(税込) です。
参考文献
- 1) Hamano H, Kawa S, Horiuchi A, et al.: High serum IgG4 concentrations in patients with sclerosing pan-creatitis. N Engl J Med 344 : 732-738, 2001.
- 2) Umehara H, Okazaki K, Masaki Y, et al.: A novel clinical entity, IgG4-related disease(IgG4RD) : gen-eral concept and details. Mod Rheumatol 22 : 1-14, 2012.
- 3) Vaglio A, Salvarani C, Buzio C : Retroperitoneal fibro-sis. Lancet 367 : 241-251, 2006.
- 4) Zen Y, Onodera M, Inoue D, et al.: Retroperitoneal fibrosis : a clinicopathologic study with respect to immunoglobulin G4. Am J Surg Pathol 33 : 1833-1839, 2009.
- 5) Yamada K, Yamamoto M, Saeki T, et al.: New clues to the nature of immunoglobulin G4-related dis-ease : a retrospective Japanese multicenter study of baseline clinical features of 334 cases. Arthritis Res Ther 19 : 262, 2017.
残りの53件を表示する
- 6) Uibu T, Oksa P, Auvinen A, et al.: Asbestos exposure as a risk factor for retroperitoneal fibrosis. Lancet 363 : 1422-1426, 2004.
- 7) van Bommel EFH, Jansen I, Hendriksz TR, et al.: Idiopathic retroperitoneal fibrosis : prospective evalu-ation of incidence and clinicoradiologic presentation. Medicine(Baltimore) 88 : 193-201, 2009.
- 8) Khosroshahi A, Carruthers MN, Stone JH, et al.: Rethinking Ormond's disease : "idiopathic" retro-peritoneal fibrosis in the era of IgG4-related disease. Medicine(Baltimore) 92 : 82-91, 2013.
- 9) Koo BS, Koh YW, Hong S, et al.: Clinicopathologic characteristics of IgG4-related retroperitoneal fibro-sis among patients initially diagnosed as having idio-pathic retroperitoneal fibrosis. Mod Rheumatol 25 : 194-198, 2015.
- 10) Wang K, Wang Z, Zeng Q, et al.: Clinical characteris-tics of IgG4-related retroperitoneal fibrosis versus idiopathic retroperitoneal fibrosis. PLoS One 16 : e0245601, 2021.
- 11) Inoue D, Yoshida K, Yoneda N, et al.: IgG4-related disease : dataset of 235 consecutive patients. Medi-cine(Baltimore) 94 : e680, 2015.
- 12) Wallace ZS, Deshpande V, Mattoo H, et al.: IgG4-related disease : Clinical and laboratory features in 125 patients. Arthritis Rheumatol 67 : 2466-2475, 2015.
- 13) Goldoni M, Bonini S, Urban ML, et al.: Asbestos and smoking as risk factors for idiopathic retroperitoneal fibrosis : a case-control study. Ann Intern Med 161 : 181-188, 2014.
- 14) Wallwork R, Perugino CA, Fu X, et al.: The associa-tion of smoking with immunoglobulin4-related Dis-ease : a case-control study. rheumatology(Oxford) 60 : 5310-5317, 2021.
- 15) Mizushima I, Kasashima S, Fujinaga Y, et al.: Clinical and pathological characteristics of IgG4-related peri-aortitis/periarteritis and retroperitoneal fibrosis diag-nosed based on experts' diagnosis. Ann Vasc Dis 12 : 460-472, 2019.
- 16) Mizushima I, Inoue D, Yamamoto M, et al.: Clinical course after corticosteroid therapy in IgG4-related aortitis/periaortitis and periarteritis : a retrospective multicenter study. Arthritis Res Ther 16 : R156, 2014.
- 17) Stone JR : Aortitis, periaortitis, and retroperitoneal fibrosis, as manifestations of IgG4-related systemic disease. Curr Opin Rheumatol 23 : 88-94, 2011.
- 18) Carruthers MN, Khosroshahi A, Augustin T, et al.: The diagnostic utility of serum IgG4 concentrations in IgG4-related disease. Ann Rheum Dis 74 : 14-18, 2015.
- 19) Yu KH, Chan TM, Tsai PH, et al.: Diagnostic perfor-mance of serum IgG4 levels in patients with IgG4-related disease. Medicine(Baltimore) 94 : e1707, 2015.
- 20) Liu Y, Zhu L, Wang Z, et al.: Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease : a retrospective study. Rheumatology(Oxford) 60 : 767-772, 2021.
- 21) Kasashima S, Kawashima A, Kasashima F, et al.: Inflammatory features, including symptoms, increased serum interleukin-6, and C-reactive protein, in IgG4-related vascular diseases. Heart Vessels 33 : 1471-1481, 2018.
- 22) Gomez Garcia I, Sanchez Castano A, Romero Molina M, et al.: Retroperitoneal fibrosis : single-centre experience from 1992 to 2010, current status of know-ledge and review of the international literature. Scand J Urol 47 : 370-377, 2013.
- 23) Li KP, Zhu J, Zhang JL, et al.: Idiopathic retroperito-neal fibrosis(RPF) : clinical features of 61 cases and literature review. Clin Rheumatol 30 : 601-605, 2011.
- 24) Zhao J, Li J, Zhang Z : Long-term outcomes and pre-dictors of a large cohort of idiopathic retroperitoneal fibrosis patients : a retrospective study. Scand J Rheumatol 48 : 239-245, 2019.
- 25) Kermani TA, Crowson CS, Achenbach SJ, et al.: Idiopathic retroperitoneal fibrosis : a retrospective review of clinical presentation, treatment, and out-comes. Mayo Clin Proc 86 : 297-303, 2011.
- 26) Moriconi D, Giannese D, Capecchi R, et al.: Risk fac-tors for relapse and longterm outcome of idiopathic retroperitoneal fibrosis. Clin Exp Nephrol 23 : 1147-1153, 2019.
- 27) Jadhav KK, Kumar V, Punatar CB, et al.: Retroperi-toneal fibrosis-clinical presentation and outcome analysis from urological perspective. Investig Clin Urol 58 : 371-377, 2017.
- 28) Labidi J, Ariba YB, Chargui S, et al.: Retroperitoneal fibrosis : a retrospective review of clinical presenta-tion, treatment and outcomes. Saudi J Kidney Dis Transpl 26 : 816-822, 2015.
- 29) Mizushima I, Inoue D, Kawano M : Retroperitoneal Fibrosis/Periaortitis and Hydronephrosis. IgG4-Related Kidney Disease(edited by Saito T, Stone JH, Nakashima H, et al), 159-171, Springer Tokyo, 2016.
- 30) Khosroshahi A, Wallace ZS, Crowe JL, et al.: Interna-tional consensus guidance statement on the manage-ment and treatment of IgG4-related disease. Arthri-tis Rheumatol 67 : 1688-1699, 2015.
- 31) Ebbo M, Grados A, Guedj E, et al.: Usefulness of 2-[18F]-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography for staging and evaluation of treatment response in IgG4-related dis-ease : a retrospective multicenter study. Arthritis Care Res(Hoboken) 66 : 86-96, 2014.
- 32) Yamamoto M, Tabeya T, Naishiro Y, et al.: Value of serum IgG4 in the diagnosis of IgG4-related disease and in differentiation from rheumatic diseases and other diseases. Mod Rheumatol 22 : 419-425, 2012.
- 33) Hourai R, Kasashima S, Sohmiya K, et al.: IgG4-posi-tive cell infiltration in various cardiovascular disor-ders-results from histopathological analysis of surgi-cal samples. BMC Cardiovasc Disord 17 : 52, 2017.
- 34) Umehara H, Okazaki K, Kawa S, et al.: The 2020 revised comprehensive diagnostic(RCD) criteria for IgG4-RD. Mod Rheumatol 31 : 529-533, 2021.
- 35) Wallace ZS, Naden RP, Chari S, et al.: The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 79 : 77-87, 2020.
- 36) Mizushima I, Yamano T, Kawahara H, et al.: Positive disease-specific autoantibodies have limited clinical significance in diagnosing IgG4-related disease in daily clinical practice. Rheumatology(Oxford) 60 : 3317-3325, 2021.
- 37) Fry AC, Singh S, Gunda SS, et al.: Successful use of steroids and ureteric stents in 24 patients with idio-pathic retroperitoneal fibrosis : a retrospective study. Nephron Clin Pract 108 : c213-c220, 2008.
- 38) Ku JH, Lee SW, Jeon HG, et al.: Percutaneous neph-rostomy versus indwelling ureteral stents in the management of extrinsic ureteral obstruction in advanced malignancies : are there differences? Urol-ogy 64 : 895-899, 2004.
- 39) Mizushima I, Kawano M : renal involvement in retro-peritoneal fibrosis : prevalence, impact and manage-ment Challenges. Int J Nephrol Renovasc Dis 14 : 279-289, 2021.
- 40) Yamamoto M, Takahashi H, Shinomura Y : Mecha-nisms and assessment of IgG4-related disease : les-sons for the rheumatologist. Nat Rev Rheumatol 10 : 148-159, 2014.
- 41) van Bommel EF, Siemes C, Hak LE, et al.: Long-term renal and patient outcome in idiopathic retroperito-neal fibrosis treated with prednisone. Am J Kidney Dis 49 : 615-625, 2007.
- 42) Chiba K, Kamisawa T, Tabata T, et al.: Clinical fea-tures of 10 patients with IgG4-related retroperito-neal fibrosis. Intern Med 52 : 1545-1551, 2013.
- 43) Alberici F, Palmisano A, Urban ML, et al.: Metho-trexate plus prednisone in patients with relapsing idiopathic retroperitoneal fibrosis. Ann Rheum Dis 72 : 1584-1586, 2013.
- 44) Binder M, Uhl M, Wiech T, et al.: Cyclophosphamide is a highly effective and safe induction therapy in chronic periaortitis : a long-term follow-up of 35 patients with chronic periaortitis. Ann Rheum Dis 71 : 311-312, 2012.
- 45) Prucha M, Kolombo I, Stadler P : Combination of ste-roids and azathioprine in the treatment of Ormond's disease-a single centre retrospective analysis. PragueMed Rep 117 : 34-41, 2016.
- 46) Scheel PJ Jr, Feeley N, Sozio SM : Combined predni-sone and mycophenolate mofetil treatment for retro-peritoneal fibrosis : a case series. Ann Intern Med 154 : 31-36, 2011.
- 47) Maritati F, Corradi D, Versari A, et al.: Rituximab therapy for chronic periaortitis. Ann Rheum Dis 71 : 1262-1264, 2012.
- 48) Vaglio A, Catanoso MG, Spaggiari L, et al.: Interleu-kin-6 as an inflammatory mediator and target of therapy in chronic periaortitis. Arthritis Rheum 65 : 2469-2475, 2013.
- 49) Della-Torre E, Campochiaro C, Bozzolo EP, et al.: Methotrexate for maintenance of remission in IgG4-related disease. Rheumatology(Oxford) 54 : 1934-1936, 2015.
- 50) Yunyun F, Yu C, Panpan Z, et al.: Efficacy of Cyclo-phosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids. Sci Rep 7 : 6195, 2017.
- 51) Yunyun F, Yu P, Panpan Z, et al.: Efficacy and safety of low dose Mycophenolate mofetil treatment for immunoglobulin G4-related disease : a randomized clinical trial. Rheumatology(Oxford) 58 : 52-60, 2019.
- 52) de Pretis N, Amodio A, Bernardoni L, et al.: Azathio-prine maintenance therapy to prevent relapses in autoimmune pancreatitis. Clin Transl Gastroenterol 8 : e90, 2017.
- 53) Fukui S, Kawaai S, Nakai T, et al.: Effectiveness and safety of Mizoribine for the treatment of IgG4-related Disease : A Retrospective Cohort Study. Rheumatology(Oxford) 60 : 5697-5704, 2021.
- 54) Carruthers MN, Topazian MD, Khosroshahi A, et al.: Rituximab for IgG4-related disease : a prospec-tive, open-label trial. Ann Rheum Dis 74 : 1171-1177, 2015.
- 55) Wallwork R, Wallace Z, Perugino C, et al.: Rituximab for idiopathic and IgG4-related retroperitoneal fibro-sis. Medicine(Baltimore) 97 : e12631, 2018.
- 56) Urban ML, Maritati F, Palmisano A, et al.: Rituximab for chronic periaortitis without evidence of IgG4-related disease : a long-term follow-up study of 20 patients. Ann Rheum Dis 79 : 433-434, 2020.
- 57) Moroni G, Gallelli B, Banfi G, et al.: Long-term out-come of idiopathic retroperitoneal fibrosis treated with surgical and/or medical approaches. Nephrol Dial Transplant 21 : 2485-2490, 2006.
- 58) Ozawa M, Fujinaga Y, Asano J, et al.: Clinical fea-tures of IgG4-related periaortitis/periarteritis based on the analysis of 179 patients with IgG4-related dis-ease : a case-control study. Arthritis Res Ther 19 : 223, 2017.
